Please provide your email address to receive an email when new articles are posted on . The points to consider advise beginning immunomodulatory therapy while diagnostic investigations continue.

GRM1 to induce M-CSF and CCL2 expression to lead to an upregulation of M2 macrophages in melanoma. This is an ASCO Meeting Abstract from the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium. This ...

Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). This is an ASCO Meeting Abstract from the 2016 ...